Afatinib Osimertinib Sequencing NIS

Inclusion Criteria: * Patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC) * The tumour harbours common EGFR mutations (Del19, L858R) at start of first-line treatment * Patients who initiated second-line osimertinib treatment for acquired T790M mutation at least 10 months prior to data entry, AND who were treated with afatinib (Gi(l)otrif®) in the first-line * Patients treated with osimertinib within an EAP/CUP or regular clinical practice * Age ≥ 18 years * Signed and dated written informed consent per regulations (Exemption of a written informed consent for NIS based on existing data in countries per local regulations and legal requirements) Exclusion Criteria: * Patients who received drug(s) other than osimertinib as the second-line treatment and/or patients who received drug(s) other than afatinib (Gi(l)otrif®) as the first-line treatment * Patients with active brain metastases at start of treatment (either afatinib/Gi(l)otrif® or osimertinib)